NEW YORK, February 10, 2017 /PRNewswire/ --
For today, Stock-Callers.com is focused on the Medical Instruments and
Massachusetts-based Waters Corp.'s stock finished Thursday's session 0.74% higher at $148.67 with a total trading volume of 334,622 shares. The Company's shares have advanced 8.08% in the past month, 5.33% in the previous three months, and 10.63% since the start of this year. The stock is trading 6.69% and 2.69% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Waters, which operates as an analytical instrument manufacturer in the US and internationally, have a Relative Strength Index (RSI) of 64.74.
On January 18th, 2017, research firm Deutsche Bank initiated a 'Buy' rating on the Company's stock, with a target price of $160 per share.
On January 24th, 2017, Waters reported Q4 2016 sales of $629 million, a 7% increase versus sales of $587 million in Q4 2015. On a GAAP basis, the Company's earnings per diluted share for Q4 2016 were up 17% to $2.15 compared to $1.83 for Q4 2015. The free research report on WAT is available at:
On Thursday, shares in Massachusetts headquartered Insulet Corp. recorded a trading volume of 278,903 shares. The stock ended the session 0.17% higher at $42.30. The Company's shares have advanced 2.67% in the last one month, 19.56% over the previous three months, and 12.26% on an YTD basis. The stock is trading 8.40% above its 50-day moving average and 14.91% above its 200-day moving average. Moreover, shares of Insulet, which develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the US, have an RSI of 58.19.
On January 23rd, 2017, Insulet announced plans to release its Q4 and full year 2016 financial results on February 27th, 2017, after the close of the financial markets. In connection with the release, the Company's management will host a conference call on the same day at 4:30 p.m. ET. The complimentary report on PODD can be downloaded at:
Shares in Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp. closed the day 1.50% higher at $43.18. The stock recorded a trading volume of 404,923 shares. The Company's shares have gained 7.71% in the previous three months and 0.66% on an YTD basis. The stock is trading 3.46% and 6.83% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Integra LifeSciences Holdings, which develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery, have an RSI of 61.57.
On January 13th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with a decrease of the target price from $85 a share to $46 a share.
On January 25th, 2017, Integra announced that its wholly-owned subsidiary, Integra Derma, Inc., is commencing a cash tender offer to purchase all outstanding common and preferred shares of Derma Sciences, Inc. (DSI) at an offer price of $7.00 per share for DSI's common stock, $32.00 per share for DSI's Series A Convertible Preferred Stock and $48.00 per share for DSI's Series B Convertible Preferred Stock. The tender offer is being made in connection with the Agreement and Plan of Merger, dated January 10th, 2017, among Integra, Integra Derma and DSI. The tender offer will expire at 12:00 midnight, ET, on February 22nd, 2017. Visit us today and download our complete research report on IART for free at:
At the close of trading on Thursday, shares in Pleasanton, California headquartered The Cooper Cos. Inc. finished 0.82% higher at $190.50. The stock recorded a trading volume of 262,093 shares. The Company's shares have advanced 4.80% in the last one month, 4.17% over the previous three months, and 8.92% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.74% and 8.98%, respectively. Furthermore, shares of Cooper Cos., which develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia, have an RSI of 74.31.
On February 01st, 2017, Cooper announced that it will release Q1 FY17 financial results on March 02nd, 2017, at 4:15 PM ET. The Company will host a conference call at 5:00 PM ET on the same day to discuss the results and current corporate developments. Get free access to your technical report on COO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All